Dyne Therapeutics, Inc. (DYN)
After hours:
| Previous close | 32.56 |
| Open | 32.61 |
| Bid | 33.64 x 100 |
| Ask | 33.70 x 100 |
| Day's range | 32.42 - 33.94 |
| 52-week range | 6.40 - 47.45 |
| Volume | |
| Avg. volume | 1,271,634 |
| Market cap | 3.381B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.58 |
| Earnings date | 28 Oct 2024 - 01 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.11 |
GlobeNewswireDyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that previously reported clinical and preclinical data across its pipeline will be featured in poster prese
Insider MonkeyDyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […]
- GlobeNewswire
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & M
